2020-02-12 Novel Coronavirus_Daily Article List

Articles publiés ou *In press*
17 références

[1]   Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, et al. The Psychological Impact of Quarantine and How to Reduce It: Rapid Review of the Evidence. Preprint withe The Lancet. 2020.
https://ssrn.com/abstract=3532534

[2]   Cabrini L, Landoni G, Zangrillo A. Minimise nosocomial spread of 2019-nCoV when treating acute respiratory failure. The Lancet.
https://doi.org/10.1016/S0140-6736(20)30359-7

[3]   Cowling BJ, Leung GM. Epidemiological research priorities for public health control of the ongoing global novel coronavirus (2019-nCoV) outbreak. Eurosurveillance. 2020.
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.6.2000110

[4]   Khan S, Nabi G, Han G, Siddique R, Lian S, Shi H, et al. Novel coronavirus: how the things are in Wuhan. Clinical Microbiology and Infection. 2020.
http://www.sciencedirect.com/science/article/pii/S1198743X20300847

[5]   Khan S, Siddique R, Ali A, Xue M, Nabi G. Novel coronavirus, poor quarantine, and the risk of pandemic. Journal of Hospital Infection. 2020.
http://www.sciencedirect.com/science/article/pii/S0195670120300487

[6]   Kui L, Fang Y-Y, Deng Y, Liu W, Wang M-F, Ma J-P, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl). 2020:10.1097/CM9.0000000000000744.
https://www.ncbi.nlm.nih.gov/pubmed/32044814

[7]   Reusken CBEM, Broberg EK, Haagmans B, Meijer A, Corman VM, Papa A, et al. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020. Eurosurveillance. 2020.
https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.6.2000082

[8]   Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. The Lancet. 2020.
https://marlin-prod.literatumonline.com/pb-assets/Lancet/pdfs/S0140673620303615.pdf

[9]   Shimizu K. 2019-nCoV, fake news, and racism. The Lancet.
https://doi.org/10.1016/S0140-6736(20)30357-3

[10]   Swerdlow DL, Finelli L. Preparation for Possible Sustained Transmission of 2019 Novel Coronavirus: Lessons From Previous Epidemics. JAMA. 2020.
https://doi.org/10.1001/jama.2020.1960

[11]	Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. An updated estimation of the risk of transmission of the novel coronavirus (2019-nCov). Infectious Disease Modelling. 2020. http://www.sciencedirect.com/science/article/pii/S246804272030004X

[12]	Tang B, Wang X, Li Q, Bragazzi NL, Tang S, Xiao Y, et al. Estimation of the Transmission Risk of the 2019-nCoV and Its Implication for Public Health Interventions. J Clin Med. 2020;9(2):E462. https://www.ncbi.nlm.nih.gov/pubmed/32046137

[13]	team Ee. Note from the editors: World Health Organization declares novel coronavirus (2019-nCoV) sixth public health emergency of international concern. Eurosurveillance. 2020;25(5):200131e. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.5.200131e

[14]	Wang L-F, Anderson DE, Mackenzie JS, Merson MH. From Hendra to Wuhan: what has been learned in responding to emerging zoonotic viruses. The Lancet. https://doi.org/10.1016/S0140-6736(20)30350-0

[15]	Wu Y. Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury. Virol Sin. 2020. https://doi.org/10.1007/s12250-020-00205-6

[16]	Xu Q. SIR Model Fit for 2019-nCOV: A Preliminary Study. 2020.

[17]	Zhang H. Early lessons from the frontline of the 2019-nCoV outbreak. The Lancet. https://doi.org/10.1016/S0140-6736(20)30356-1

Preprints
31 références

[Un rappel : il s'agit de rapports préliminaires qui n'ont pas fait l'objet d'un examen par les pairs. Ils ne doivent pas être considérés comme concluants, ni guider la pratique clinique ou les comportements liés à la santé, ni être présentés dans les médias comme des informations établies.]

[1]	Abdelmageed MI, Abdelmoneim AH, Mustafa MI, Elfadol NM, Murshed NS, Shantier SW, et al. Design of multi epitope-based peptide vaccine against E protein of human 2019-nCoV: An immunoinformatics approach. bioRxiv. 2020:2020.02.04.934232. https://www.biorxiv.org/content/biorxiv/early/2020/02/11/2020.02.04.934232.full.pdf
[2]	Bao L, Deng W, Huang B, Gao H, Ren L, Wei Q, et al. The Pathogenicity of 2019 Novel Coronavirus in hACE2 Transgenic Mice. bioRxiv. 2020:2020.02.07.939389. https://www.biorxiv.org/content/biorxiv/early/2020/02/11/2020.02.07.939389.full.pdf
[3]	Blumberg S, Lietman TM, Porco TC. Assessing the plausibility of subcritical transmission of 2019-nCoV in the United States. medRxiv. 2020:2020.02.08.20021311. http://medrxiv.org/content/early/2020/02/11/2020.02.08.20021311.abstract
[4]	Cai G. Tobacco-use disparity in gene expression of ACE2, the receptor of 2019-nCov. medRxiv. 2020:2020.02.05.20020107. http://medrxiv.org/content/early/2020/02/11/2020.02.05.20020107.abstract

[5]   Chinazzi M, Davis JT, Ajelli M, Gioannini C, Litvinova M, Merler S, et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (2019-nCoV) outbreak. medRxiv. 2020:2020.02.09.20021261.
http://medrxiv.org/content/early/2020/02/11/2020.02.09.20021261.abstract

[6]   Flynn J, Purushotham D, Choudhary MN, Zhuo X, Fan C, Matt G, et al. Exploring the coronavirus epidemic using the new WashU Virus Genome Browser. bioRxiv. 2020:2020.02.07.939124.
https://www.biorxiv.org/content/biorxiv/early/2020/02/11/2020.02.07.939124.full.pdf

[7]   Gorbalenya AE. Severe acute respiratory syndrome-related coronavirus – The species and its viruses, a statement of the Coronavirus Study Group. bioRxiv. 2020:2020.02.07.937862.
https://www.biorxiv.org/content/biorxiv/early/2020/02/11/2020.02.07.937862.full.pdf

[8]   Hébert-Dufresne L, Althouse BM, Scarpino SV, Allard A. Beyond R_0: the importance of contact tracing when predicting epidemics. medRxiv. 2020:2020.02.10.20021725.
https://www.medrxiv.org/content/medrxiv/early/2020/02/12/2020.02.10.20021725.full.pdf

[9]   Hellewell J, Abbott S, Gimma A, Bosse NI, Jarvis CI, Russell TW, et al. Feasibility of controlling 2019-nCoV outbreaks by isolation of cases and contacts. medRxiv. 2020:2020.02.08.20021162.
http://medrxiv.org/content/early/2020/02/11/2020.02.08.20021162.abstract

[10]   Labadin J, Hong BH. Transmission Dynamics of 2019-nCoV in Malaysia. medRxiv. 2020:2020.02.07.20021188.
http://medrxiv.org/content/early/2020/02/11/2020.02.07.20021188.abstract

[11]   Li J, Li S, Cai Y, Liu Q, Li X, Zeng Z, et al. Epidemiological and Clinical Characteristics of 17 Hospitalized Patients with 2019 Novel Coronavirus Infections Outside Wuhan, China. medRxiv. 2020:2020.02.11.20022053.
https://www.medrxiv.org/content/medrxiv/early/2020/02/12/2020.02.11.20022053.full.pdf

[12]   Li X, Zhao X, Sun Y. The lockdown of Hubei Province causing different transmission dynamics of the novel coronavirus (2019-nCoV) in Wuhan and Beijing. medRxiv. 2020:2020.02.09.20021477.
http://medrxiv.org/content/early/2020/02/11/2020.02.09.20021477.abstract

[13]   Liang W, Rao S, Xiao C, Lin Z, Zhang Q, Qi W. Diarrhea may be underestimated: a missing link in 2019 novel coronavirus. medRxiv. 2020:2020.02.03.20020289.
http://medrxiv.org/content/early/2020/02/11/2020.02.03.20020289.abstract

[14]   Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, et al. Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage. medRxiv. 2020:2020.02.10.20021584.
https://www.medrxiv.org/content/medrxiv/early/2020/02/12/2020.02.10.20021584.full.pdf

[15]   Liu Q, Li D, Liu Z, Gao Z, Zhu J, Yang J, et al. EPIDEMIC TRENDS ANALYSIS AND RISK ESTIMATION OF 2019-NCOV OUTBREAK. medRxiv. 2020:2020.02.09.20021444.
http://medrxiv.org/content/early/2020/02/11/2020.02.09.20021444.abstract

[16]   Luczak-Roesch M. Networks of information token recurrences derived from genomic sequences may reveal hidden patterns in epidemic outbreaks: A case study of the 2019-nCoV coronavirus. medRxiv. 2020:2020.02.07.20021139.
http://medrxiv.org/content/early/2020/02/11/2020.02.07.20021139.abstract

[17]   Meng T, Cao H, Zhang H, Kang Z, Xu D, Gong H, et al. The transmembrane serine protease inhibitors are potential antiviral drugs for 2019-nCoV targeting the insertion sequence-induced viral infectivity enhancement. bioRxiv. 2020:2020.02.08.926006.
https://www.biorxiv.org/content/biorxiv/early/2020/02/11/2020.02.08.926006.full.pdf

[18]   Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S, Hayashi K, et al. Estimation of the asymptomatic ratio of novel coronavirus (2019-nCoV) infections among passengers on evacuation flights. medRxiv. 2020:2020.02.03.20020248.
http://medrxiv.org/content/early/2020/02/11/2020.02.03.20020248.abstract

[19]   Sanche S, Lin YT, Xu C, Romero-Severson E, Hengartner N, Ke R. The Novel Coronavirus, 2019-nCoV, is Highly Contagious and More Infectious Than Initially Estimated. medRxiv. 2020:2020.02.07.20021154.
http://medrxiv.org/content/early/2020/02/11/2020.02.07.20021154.abstract

[20]   Sarkar B, Ullah MA, Johora FT, Taniya MA, Araf Y. The Essential Facts of Wuhan Novel Coronavirus Outbreak in China and Epitope-based Vaccine Designing against 2019-nCoV. bioRxiv. 2020:2020.02.05.935072.
https://www.biorxiv.org/content/biorxiv/early/2020/02/11/2020.02.05.935072.full.pdf

[21]   Tian H, Li Y, Liu Y, Kraemer MUG, Chen B, Cai J, et al. Early evaluation of Wuhan City travel restrictions in response to the 2019 novel coronavirus outbreak. medRxiv. 2020:2020.01.30.20019844.
http://medrxiv.org/content/early/2020/02/11/2020.01.30.20019844.abstract

[22]   Wan S, Yi Q, Fan S, Lv J, Zhang X, Guo L, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). medRxiv. 2020:2020.02.10.20021832.
https://www.medrxiv.org/content/medrxiv/early/2020/02/12/2020.02.10.20021832.full.pdf

[23]   Wu H, Huang J, Zhang CJP, He Z, Ming W-k. Facemask shortage and the novel coronavirus (2019-nCoV) outbreak: Reflection on public health measures. medRxiv. 2020:2020.02.11.20020735.
http://medrxiv.org/content/early/2020/02/12/2020.02.11.20020735.abstract

[24]   Xiong H, Yan H. Simulating the infected population and spread trend of 2019-nCov under different policy by EIR model. medRxiv. 2020:2020.02.10.20021519.
http://medrxiv.org/content/early/2020/02/12/2020.02.10.20021519.abstract

[25]   Xu Z, Qian Y, Fang L, Yao M. Primary Care Practitioners' Response to 2019 Novel Coronavirus Outbreak in China. medRxiv. 2020:2020.02.11.20022095.
https://www.medrxiv.org/content/medrxiv/early/2020/02/12/2020.02.11.20022095.full.pdf

[26]   Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv. 2020:2020.02.10.20021675.
http://medrxiv.org/content/early/2020/02/11/2020.02.10.20021675.abstract

[27]   Yang Y, Yang M, Shen C, Wang F, Yuan J, Li J, et al. Laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections [ou Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections]. medRxiv. 2020:2020.02.11.20021493.
http://medrxiv.org/content/early/2020/02/12/2020.02.11.20021493.abstract

[28]   You C, Deng Y, Hu W, Sun J, Lin Q, Zhou F, et al. Estimation of the Time-Varying Reproduction Number of 2019-nCoV Outbreak in China. medRxiv. 2020:2020.02.08.20021253.
http://medrxiv.org/content/early/2020/02/11/2020.02.08.20021253.abstract

[29]   Zhao X, Liu X, Li X. Tracking the spread of novel coronavirus (2019-nCoV) based on big data. medRxiv. 2020:2020.02.07.20021196.
http://medrxiv.org/content/early/2020/02/11/2020.02.07.20021196.abstract

[30]   Zhou Y, Zeng Y, Tong Y, Chen C. Ophthalmologic evidence against the interpersonal transmission of 2019 novel coronavirus through conjunctiva. medRxiv. 2020:2020.02.11.20021956.
https://www.medrxiv.org/content/medrxiv/early/2020/02/12/2020.02.11.20021956.full.pdf

[31]   Zhu X, Zhang A, Xu S, Jia P, Tan X, Tian J, et al. Spatially Explicit Modeling of 2019-nCoV Epidemic Trend based on Mobile Phone Data in Mainland China. medRxiv. 2020:2020.02.09.20021360.
http://medrxiv.org/content/early/2020/02/11/2020.02.09.20021360.abstract

Documents gouvernementaux

11 références

[1]   Australian Government. Department of health. Nouvelles fiches d'information [mis à jour le 12 février]. Australian Government. Department of health; 2020. [consulté le 05/02/2020]. Disponible: https://www.health.gov.au/resources?search_api_views_fulltext=2019-nCoV

[2]   Canada Gd. Nouveau coronavirus de 2019 : Mise à jour sur l'éclosion [En ligne]. : 2020. [modifié le ; cité le]. Disponible: https://www.canada.ca/fr/sante-publique/services/maladies/2019-nouveau-coronavirus.html

[3]   CDC. Healthcare Professionals: Frequently Asked Questions and Answers [mis à jour le 9 février] [En ligne]. : 2020. [modifié le ; cité le]. Disponible: https://www.cdc.gov/coronavirus/2019-ncov/hcp/faq.html

[4]   CDC. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection [mis à jour le 11/02/2020]. 2020. Disponible: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html

[5]   CDC. Frequently Asked Questions and Answers [En ligne]. : 2020. [modifié le ; cité le]. Disponible: https://www.cdc.gov/coronavirus/2019-ncov/faq.html

[6]   CDC. Information for Laboratories [mis à jour le 11/02/2020] [En ligne]. : 2020. [modifié le ; cité le]. Disponible: https://www.cdc.gov/coronavirus/2019-ncov/lab/index.html

[7]   England PH. Interim guidance for first responders and others in close contact with symptomatic people with potential 2019-nCoV [mis à jour le 11/02/2020] [En ligne]. : 2020. [modifié le ; cité le]. Disponible: https://www.gov.uk/government/publications/novel-coronavirus-2019-ncov-interim-guidance-for-first-responders/interim-guidance-for-first-responders-and-others-in-close-contact-with-symptomatic-people-with-potential-2019-ncov

[8]   Public Health England. Novel coronavirus (2019-nCoV): epidemiology, virology and clinical features. Guidance [Mis à jour le 10/02/2020]. PHE; 2020. [consulté le 03/02/2020]. Disponible: https://www.gov.uk/government/publications/wuhan-novel-coronavirus-background-information

[9]   Public Health England. Investigation and initial clinical management of possible cases of novel coronavirus (2019-nCoV) infection. Guidance [Mis à jour le 11/02/2020] [En ligne]. : Public Health England; 2020. [modifié le 07/02/2020; cité le 06/02/2020]. Disponible: https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection

[10]   Public Health England. Novel coronavirus (2019-nCoV): guidance for sampling and for diagnostic laboratories [Mis à jour le 11/02/2020] [En ligne]. : Public Health England; 2020. [modifié le 05/02/2020; cité le]. Disponible: https://www.gov.uk/government/publications/wuhan-novel-coronavirus-guidance-for-clinical-diagnostic-laboratories

[11]   WHO. Novel Coronavirus(2019-nCoV) - Situation Report – 22. 2020. Disponible: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2

Articles en chinois et coréen

1 référence

[Un résumé en anglais est disponible]

[1]   Group of Interventional Respiratory Medicine CTS. [Expert consensus for bronchoscopy during the epidemic of 2019 Novel Coronavirus infection (Trial version)]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E006.

News
9 références

[1]   Coronavirus latest: WHO officially names disease COVID-19. Nature. 2020 (col. 12/02/2020).
Disponible: https://www.nature.com/articles/d41586-020-00154-w

[2]   Fake face masks emerge as coronavirus fear grips China. Securing Industry. 2020.
Disponible: https://www.securingindustry.com/cosmetics-and-personal-care/fake-face-masks-
emerge-as-coronavirus-fear-grips-china/s106/a11303/

[3]   Chavez N. OTIS MotherToBaby Issues Statement on Coronaviruses and Pregnancy. BDR
Connection. 2020. Disponible: https://connection.birthdefectsresearch.org/p/bl/et/blogaid=1354
[4]   Cyranoski D. Did pangolins spread the China coronavirus to people? Nature. 2020 (col.
12/02/2020). Disponible: https://www.nature.com/articles/d41586-020-00364-
2?utm_source=twt_nnc&utm_medium=social&utm_campaign=naturenews

[5]   Infectiologie.com. COVID-19: nouveau coronavirus. 2020 (col. 12/02/2020). Disponible:
https://www.infectiologie.com/fr/actualites/covid-19-nouveau-coronavirus_-n.html

[6]   Kar-Gupta S. Biotech company Novacyt seeks emergency approval for coronavirus test.
Reuters. 2020. Disponible: https://www.reuters.com/article/us-china-health-novacyt/biotech-
company-novacyt-seeks-emergency-approval-for-coronavirus-test-idUSKBN2010Q8

[7]   KARLIN-SMITH S. FDA: No drug shortages reported because of coronavirus but situation
'fluid'. Politico. 2020. Disponible: https://www.politico.com/news/2020/02/07/chinese-drugs-
shortage-coronavirus-112049

[8]   Lisa S. Deaths from newly named coronavirus disease top 1,000. CIDRAP. 2020 (col.
12/02/2020). Disponible: http://www.cidrap.umn.edu/news-perspective/2020/02/deaths-newly-
named-coronavirus-disease-top-1000

[9]   Schnirring L. China nCoV cases top 40,000, with more tied to French cluster. CIDRAP. 2020.
Disponible: http://www.cidrap.umn.edu/news-perspective/2020/02/china-ncov-cases-top-40000-
more-tied-french-cluster